News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca PLC’s Recentin Flunks Colon Cancer Tests
May 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file experimental cancer drug Recentin as a first-line treatment for colon cancer on Friday after disappointing results from a second pivotal clinical trial with the medicine.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
IN PARTNERSHIP WITH TRUVETA
Webinar: AI for Faster, More Precise Real-World Research: Extracting Clinical Notes Data at Scale
August 27, 2025
·
1 min read
·
BioSpace Insights
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
August 27, 2025
·
3 min read
·
Dan Samorodnitsky
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
August 27, 2025
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
August 27, 2025
·
1 min read
·
Jef Akst
